NO963551L - Terapeutisk middel for behandling av lipidmetabolismeforstyrrelser - Google Patents
Terapeutisk middel for behandling av lipidmetabolismeforstyrrelserInfo
- Publication number
- NO963551L NO963551L NO963551A NO963551A NO963551L NO 963551 L NO963551 L NO 963551L NO 963551 A NO963551 A NO 963551A NO 963551 A NO963551 A NO 963551A NO 963551 L NO963551 L NO 963551L
- Authority
- NO
- Norway
- Prior art keywords
- therapeutic agent
- lipid metabolism
- disorder
- treatment
- present
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 4
- 229940124597 therapeutic agent Drugs 0.000 title abstract 4
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000035762 Disorder of lipid metabolism Diseases 0.000 abstract 3
- 206010021024 Hypolipidaemia Diseases 0.000 abstract 2
- 208000037157 Azotemia Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 230000001919 adrenal effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 208000009928 nephrosis Diseases 0.000 abstract 1
- 231100001027 nephrosis Toxicity 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 230000006016 thyroid dysfunction Effects 0.000 abstract 1
- 208000009852 uremia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6337884A JPH08176007A (ja) | 1994-12-27 | 1994-12-27 | 脂質代謝異常治療剤 |
| PCT/JP1995/002707 WO1996020004A1 (en) | 1994-12-27 | 1995-12-27 | Therapeutic agent for disorder of lipid metabolism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO963551D0 NO963551D0 (no) | 1996-08-26 |
| NO963551L true NO963551L (no) | 1996-10-25 |
| NO318099B1 NO318099B1 (no) | 2005-01-31 |
Family
ID=18312906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19963551A NO318099B1 (no) | 1994-12-27 | 1996-08-26 | Anvendelse av Tumorcytotoksisk Faktor-II for fremstilling av et terapeutisk middel til behandling av hyperkolesterolemi og til okning av aktiviteten til lechitinkolesterolacyltransferase |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0754051B1 (no) |
| JP (1) | JPH08176007A (no) |
| KR (1) | KR100395695B1 (no) |
| AT (1) | ATE247975T1 (no) |
| AU (1) | AU710513B2 (no) |
| CA (1) | CA2184248A1 (no) |
| DE (1) | DE69531608T2 (no) |
| DK (1) | DK0754051T3 (no) |
| ES (1) | ES2201128T3 (no) |
| FI (1) | FI115826B (no) |
| HU (1) | HU220139B (no) |
| NO (1) | NO318099B1 (no) |
| NZ (1) | NZ298141A (no) |
| TW (1) | TW480173B (no) |
| WO (1) | WO1996020004A1 (no) |
| ZA (1) | ZA9510981B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4006058B2 (ja) | 1997-03-11 | 2007-11-14 | 第一三共株式会社 | 多臓器不全予防及び／又は治療剤 |
| KR100568664B1 (ko) * | 1997-03-14 | 2006-06-13 | 다이이치세이야꾸 가부시끼가이샤 | 악액질 예방 및/또는 치료제 |
| WO1998041230A1 (fr) | 1997-03-14 | 1998-09-24 | Snow Brand Milk Products Co., Ltd. | Agent preventif et/ou curatif de la cachexie |
| EP0973914B1 (en) | 1997-04-11 | 2006-12-13 | Takeda Pharmaceutical Company Limited | Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
| JPH1129493A (ja) * | 1997-07-14 | 1999-02-02 | Snow Brand Milk Prod Co Ltd | 放射線障害予防及び／又は治療剤 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| DE69334087T2 (de) * | 1992-07-16 | 2007-07-05 | Daiichi Pharmaceutical Co., Ltd. | Arzneimittelzusammensetzung enthaltend TCF-II |
-
1994
- 1994-12-27 JP JP6337884A patent/JPH08176007A/ja not_active Withdrawn
- 1994-12-27 NZ NZ298141A patent/NZ298141A/xx not_active IP Right Cessation
-
1995
- 1995-12-16 TW TW084113453A patent/TW480173B/zh not_active IP Right Cessation
- 1995-12-27 ZA ZA9510981A patent/ZA9510981B/xx unknown
- 1995-12-27 DK DK95942270T patent/DK0754051T3/da active
- 1995-12-27 HU HU9602341A patent/HU220139B/hu not_active IP Right Cessation
- 1995-12-27 CA CA002184248A patent/CA2184248A1/en not_active Abandoned
- 1995-12-27 KR KR1019960704608A patent/KR100395695B1/ko not_active IP Right Cessation
- 1995-12-27 ES ES95942270T patent/ES2201128T3/es not_active Expired - Lifetime
- 1995-12-27 WO PCT/JP1995/002707 patent/WO1996020004A1/en active IP Right Grant
- 1995-12-27 DE DE69531608T patent/DE69531608T2/de not_active Expired - Fee Related
- 1995-12-27 AT AT95942270T patent/ATE247975T1/de not_active IP Right Cessation
- 1995-12-27 EP EP95942270A patent/EP0754051B1/en not_active Expired - Lifetime
- 1995-12-27 AU AU43550/96A patent/AU710513B2/en not_active Ceased
-
1996
- 1996-08-26 NO NO19963551A patent/NO318099B1/no not_active IP Right Cessation
- 1996-08-26 FI FI963312A patent/FI115826B/fi active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| DE69531608T2 (de) | 2004-02-19 |
| NO963551D0 (no) | 1996-08-26 |
| EP0754051B1 (en) | 2003-08-27 |
| NO318099B1 (no) | 2005-01-31 |
| WO1996020004A1 (en) | 1996-07-04 |
| HUT76085A (en) | 1997-06-30 |
| ATE247975T1 (de) | 2003-09-15 |
| JPH08176007A (ja) | 1996-07-09 |
| KR100395695B1 (ko) | 2004-02-14 |
| FI963312A0 (fi) | 1996-08-26 |
| CA2184248A1 (en) | 1996-07-04 |
| HU9602341D0 (en) | 1996-10-28 |
| NZ298141A (en) | 2000-12-22 |
| DE69531608D1 (de) | 2003-10-02 |
| HU220139B (hu) | 2001-11-28 |
| KR970701058A (ko) | 1997-03-17 |
| ES2201128T3 (es) | 2004-03-16 |
| AU710513B2 (en) | 1999-09-23 |
| AU4355096A (en) | 1996-07-19 |
| ZA9510981B (en) | 1996-07-17 |
| DK0754051T3 (da) | 2003-09-29 |
| FI115826B (fi) | 2005-07-29 |
| FI963312A (fi) | 1996-08-26 |
| EP0754051A1 (en) | 1997-01-22 |
| TW480173B (en) | 2002-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9601846D0 (en) | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | |
| DK0975367T3 (da) | Forbedret afgivelse af lægemidler til slimhindeoverflader | |
| BE1002710A5 (fr) | Preparation au diclofenac sodique a effet prolonge. | |
| BRPI0413326A (pt) | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel | |
| BR0114526A (pt) | Composições e métodos para reduzir as lipoproteinas(a) plasmáticas e os fatores de risco de doenças cardiovasculares | |
| ES2053198T3 (es) | Sistema de suministro de un farmaco de glucano y adyuvante. | |
| AU6171796A (en) | Prodrugs of pharmaceuticals with improved bioavailability | |
| IL160643A0 (en) | Combination dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor, and aspirin | |
| TNSN98017A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| DE69827777D1 (de) | Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie | |
| DK1165537T3 (da) | Hydroxymatairesinol til forebyggelse af cancer | |
| WO2001017517A3 (en) | Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer | |
| DE69916248D1 (de) | D-chiro-inositol-enthaltende zusammensetzungen zur behandlung von metabolischen krankheiten, die durch hyperandrogenismund/oder anovulation gekennzeichnet sind | |
| DE69434121D1 (de) | Pharmazeutische zusammensetzung zur immunstimulierenden therapie | |
| DK0696456T3 (da) | Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme | |
| HUP0003982A3 (en) | The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function | |
| NO963551D0 (no) | Terapeutisk middel for behandling av lipidmetabolismeforstyrrelser | |
| PT1007055E (pt) | Utilizacao de amifostina | |
| DK1035859T3 (da) | Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler | |
| ZA968990B (en) | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases. | |
| Sen et al. | Cystathionine-β-synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells | |
| DE69841573D1 (de) | Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose | |
| IT1293067B1 (it) | Composizione farmaceutica per il trattamento di patologie causate da alterato metabolismo lipidico | |
| PL368572A1 (en) | Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections | |
| WO2004080488A3 (de) | Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |